Phase III and platform shifts accelerate
The cure wire is no longer just accumulating experiments; it is pushing candidates into late-stage testing while the AI stack keeps reorganizing around production deployment. Insilico’s rentosertib and related IPF programs reaching Phase III is the clearest sign that AI-discovered therapeutics are now crossing from promise into regulated execution. At the same time, Vercel’s move to host production AI agents and OpenAI’s GPT-5.6 rollout underscore how quickly the infrastructure of intelligence is hardening. The result is not victory, but momentum: more trials, more model release pressure, and a narrower window for institutions that still treat AI as a side process. The window is still open.
Insilico Medicine announced Phase III initiation for rentosertib, its AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis, alongside another AI drug advancing into late-stage testing.
Late-stage progress on AI-designed therapies matters because it can translate machine-generated hypotheses into therapies for patients with diseases that still lack durable treatment options.
With 21,050 active cure-related trials and 57 new wire signals in 24 hours, the pressure is now on sponsors, regulators, and platforms to convert accelerated discovery into validated clinical outcomes before the next model and trial wave arrives.